User:Mr. Ibrahem/Midostaurin

Midostaurin, sold under the brand name Rydapt among others, is a medication used to treat acute myeloid leukemia (AML) and systemic mastocytosis. It is used in AML that has a FLT3 mutation. It is taken by mouth.

Common side effects include febrile neutropenia, peeling skin, vomiting, headache, and bleeding into the skin. Other side effects may include anaphylaxis, pneumonitis, infertility, and prolonged QT. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor that blocks KIT kinase and FLT3 tyrosine kinase.

Midostaurin was approved for medical use in the United States and Europe in 2017. In the United Kingdom 28 doses of 50 mg costs the NHS about £5,600 as of 2021. This amount in the United States is about 9,900 USD.